logo

Alpha-glucosidase Inhibitors Market Size (2024 - 2029)

The Alpha-glucosidase Inhibitors Market is projected to experience growth over the forecast period, driven by their use as oral anti-diabetic drugs for managing type 2 diabetes. These inhibitors play a crucial role in glycemic control by preventing carbohydrate digestion, thereby reducing blood sugar impact. Their potential application extends to COVID-19 patients, highlighting their versatility as glucose-lowering agents. The market's expansion is supported by global health initiatives aimed at improving diabetes treatment access and transparency, addressing the increasing prevalence of diabetes and impaired glucose tolerance in various regions.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Inhibitors Research Alpha Glucosidase Inhibitors Industry Market Size

Market Size of Alpha-glucosidase Inhibitors Industry

Alpha-glucosidase Inhibitors Market Summary
Study Period 2018 - 2029
Market Size (2024) USD 4.76 Billion
Market Size (2029) USD 5.30 Billion
CAGR (2024 - 2029) 2.17 %
Fastest Growing Market Middle East and Africa
Largest Market Asia Pacific
Market Concentration High

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Alpha-glucosidase Inhibitors Market Analysis

The Alpha-glucosidase Inhibitors Market size is estimated at USD 4.76 billion in 2024, and is expected to reach USD 5.30 billion by 2029, growing at a CAGR of 2.17% during the forecast period (2024-2029).

Alpha-glucosidase inhibitors are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates. Carbohydrates are converted into monosaccharides by alpha-glucosidase enzymes present in cells lining the intestine, enabling monosaccharides to be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of dietary carbohydrates on blood sugar. 

Alpha-glucosidase inhibitors are used to establish greater glycemic control over hyperglycemia in diabetes mellitus type 2, they may be used as monotherapy in conjunction with an appropriate diabetic diet and exercise, or they may be used in conjunction with other anti-diabetic drugs. Therefore, they have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.

73 million adults were living with diabetes in the IDF MENA Region, which is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region are living with Impaired Glucose Tolerance, which increases their risk of developing type 2 diabetes.

The World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to medicines and health products for the treatment of diabetes and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Alpha-glucosidase Inhibitors Industry Segmentation

Alpha-glucosidase inhibitors are a class of drugs used in treating type 2 diabetes mellitus alone or combined with other antidiabetic drugs that are particularly useful for reducing postprandial hyperglycemia. The Alpha-glucosidase Inhibitors Market is segmented into Geography. The report offers the value (in USD) and volume (in Units) for the above segments.

Geography
North America
United States
Canada
Rest of North America
Europe
France
Germany
Italy
Spain
United Kingdom
Russia
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Asia-Pacific
Japan
South Korea
China
India
Australia
Vietnam
Malaysia
Indonesia
Philippines
Thailand
Rest of Asia-Pacific
Middle East and Africa
Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
Need A Different Region Or Segment?
Customize Now

Alpha-glucosidase Inhibitors Market Size Summary

The Alpha-glucosidase Inhibitors Market is poised for growth, driven by the increasing prevalence of type 2 diabetes and the rising demand for effective diabetes management solutions. These oral anti-diabetic drugs play a crucial role in controlling blood sugar levels by inhibiting the digestion of carbohydrates, thereby reducing the impact of dietary carbohydrates on blood glucose levels. The market is supported by global health initiatives and resolutions aimed at enhancing diabetes prevention and control, as well as improving access to diabetes medications. The World Health Assembly and WHO's Global Diabetes Compact are pivotal in promoting equitable and comprehensive diabetes care, particularly in low and middle-income countries. This supportive regulatory environment, coupled with the growing diabetes population, is expected to propel the market forward during the forecast period.

The market landscape is characterized by a diverse range of manufacturers, including major players like Bayer, SunPharma, Pfizer, Takeda, and Zydus, who hold a significant global presence. The Middle East and Africa region is anticipated to experience notable growth, reflecting the increasing demand for quality healthcare services and the government's efforts to enhance healthcare access and affordability. The market's expansion is further bolstered by the development and approval of key medications such as Acarbose, Voglibose, and Miglitol, which are instrumental in managing postprandial blood sugar levels. Regulatory actions, such as price control measures and guidance on generic formulations, also contribute to the market's dynamic nature. Overall, the Alpha-glucosidase Inhibitors Market is set to grow, driven by a combination of health trends, regulatory support, and innovative pharmaceutical developments.

Explore More

Alpha-glucosidase Inhibitors Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Alpha-glucosidase Inhibitors

    2. 2.2 Geography

      1. 2.2.1 North America

        1. 2.2.1.1 United States

        2. 2.2.1.2 Canada

        3. 2.2.1.3 Rest of North America

      2. 2.2.2 Europe

        1. 2.2.2.1 France

        2. 2.2.2.2 Germany

        3. 2.2.2.3 Italy

        4. 2.2.2.4 Spain

        5. 2.2.2.5 United Kingdom

        6. 2.2.2.6 Russia

        7. 2.2.2.7 Rest of Europe

      3. 2.2.3 Latin America

        1. 2.2.3.1 Mexico

        2. 2.2.3.2 Brazil

        3. 2.2.3.3 Rest of Latin America

      4. 2.2.4 Asia-Pacific

        1. 2.2.4.1 Japan

        2. 2.2.4.2 South Korea

        3. 2.2.4.3 China

        4. 2.2.4.4 India

        5. 2.2.4.5 Australia

        6. 2.2.4.6 Vietnam

        7. 2.2.4.7 Malaysia

        8. 2.2.4.8 Indonesia

        9. 2.2.4.9 Philippines

        10. 2.2.4.10 Thailand

        11. 2.2.4.11 Rest of Asia-Pacific

      5. 2.2.5 Middle East and Africa

        1. 2.2.5.1 Saudi Arabia

        2. 2.2.5.2 Iran

        3. 2.2.5.3 Egypt

        4. 2.2.5.4 Oman

        5. 2.2.5.5 South Africa

        6. 2.2.5.6 Rest of Middle East and Africa

Alpha-glucosidase Inhibitors Market Size FAQs

The Alpha-glucosidase Inhibitors Market size is expected to reach USD 4.76 billion in 2024 and grow at a CAGR of 2.17% to reach USD 5.30 billion by 2029.

In 2024, the Alpha-glucosidase Inhibitors Market size is expected to reach USD 4.76 billion.

Alpha Glucosidase Inhibitors Market Report Snapshots

Alpha Glucosidase Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)